KR101475088B1 - 아자-벤조티오페닐 화합물 및 사용 방법 - Google Patents
아자-벤조티오페닐 화합물 및 사용 방법 Download PDFInfo
- Publication number
- KR101475088B1 KR101475088B1 KR1020097005785A KR20097005785A KR101475088B1 KR 101475088 B1 KR101475088 B1 KR 101475088B1 KR 1020097005785 A KR1020097005785 A KR 1020097005785A KR 20097005785 A KR20097005785 A KR 20097005785A KR 101475088 B1 KR101475088 B1 KR 101475088B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- alkyl
- compound
- iii
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*C1CC(CCCC2CC(C)CC2)C1 Chemical compound C*C1CC(CCCC2CC(C)CC2)C1 0.000 description 5
- RKGXJBAAWCGBQA-UHFFFAOYSA-N CC(C)OC1CCNCC1 Chemical compound CC(C)OC1CCNCC1 RKGXJBAAWCGBQA-UHFFFAOYSA-N 0.000 description 1
- MEZCQZJDXVJARQ-UHFFFAOYSA-N CC(C)OC1CCOCC1 Chemical compound CC(C)OC1CCOCC1 MEZCQZJDXVJARQ-UHFFFAOYSA-N 0.000 description 1
- OIELPWFWJPVOLK-UHFFFAOYSA-N CC(C)OC1CNCCC1 Chemical compound CC(C)OC1CNCCC1 OIELPWFWJPVOLK-UHFFFAOYSA-N 0.000 description 1
- IYKVTPKGWBIZFR-ZETCQYMHSA-N CC(C)O[C@@H]1CNCC1 Chemical compound CC(C)O[C@@H]1CNCC1 IYKVTPKGWBIZFR-ZETCQYMHSA-N 0.000 description 1
- NDLIXOHGEJHPLU-UHFFFAOYSA-N CCOC(c([s]c(c1cnc2)c2F)c1Nc(c(F)c1)ccc1I)=O Chemical compound CCOC(c([s]c(c1cnc2)c2F)c1Nc(c(F)c1)ccc1I)=O NDLIXOHGEJHPLU-UHFFFAOYSA-N 0.000 description 1
- CYGMOZMKKSKPSB-UHFFFAOYSA-N CCOC(c([s]c1c2C=CN(C)C1)c2Nc(c(F)c1)ccc1S)=O Chemical compound CCOC(c([s]c1c2C=CN(C)C1)c2Nc(c(F)c1)ccc1S)=O CYGMOZMKKSKPSB-UHFFFAOYSA-N 0.000 description 1
- LPSHVWAZAPVRAV-UHFFFAOYSA-N CN(c1c(C(NOCCO)=O)[s]c2c1cncc2)c(ccc(I)c1)c1F Chemical compound CN(c1c(C(NOCCO)=O)[s]c2c1cncc2)c(ccc(I)c1)c1F LPSHVWAZAPVRAV-UHFFFAOYSA-N 0.000 description 1
- AVPAYFOQPGPSCC-UHFFFAOYSA-N COC1CNC1 Chemical compound COC1CNC1 AVPAYFOQPGPSCC-UHFFFAOYSA-N 0.000 description 1
- BHRMALFLMOQGQT-SNVBAGLBSA-N COc(cncc12)c1[s]c(C(NOC[C@@H](CO)O)=O)c2Nc(c(F)c1)ccc1I Chemical compound COc(cncc12)c1[s]c(C(NOC[C@@H](CO)O)=O)c2Nc(c(F)c1)ccc1I BHRMALFLMOQGQT-SNVBAGLBSA-N 0.000 description 1
- MMKZQWCBHJTIFM-GFCCVEGCSA-N Cc(cc(cc1)I)c1Nc1c(C(NOC[C@@H](CO)O)=O)[s]c2ccncc12 Chemical compound Cc(cc(cc1)I)c1Nc1c(C(NOC[C@@H](CO)O)=O)[s]c2ccncc12 MMKZQWCBHJTIFM-GFCCVEGCSA-N 0.000 description 1
- UUXFVQLIBFSRSA-LLVKDONJSA-N N#Cc(cncc12)c1[s]c(C(NOC[C@@H](CO)O)=O)c2Nc(ccc(I)c1)c1F Chemical compound N#Cc(cncc12)c1[s]c(C(NOC[C@@H](CO)O)=O)c2Nc(ccc(I)c1)c1F UUXFVQLIBFSRSA-LLVKDONJSA-N 0.000 description 1
- IKMHWEQYAYOHSC-UHFFFAOYSA-N NC(c([s]c1c2ccnc1)c2Nc(c(F)c1)ccc1I)=O Chemical compound NC(c([s]c1c2ccnc1)c2Nc(c(F)c1)ccc1I)=O IKMHWEQYAYOHSC-UHFFFAOYSA-N 0.000 description 1
- JMGCRSWSPLNDDC-UHFFFAOYSA-N NC(c([s]c1c2cncc1)c2Nc(c(F)c1)ccc1I)=O Chemical compound NC(c([s]c1c2cncc1)c2Nc(c(F)c1)ccc1I)=O JMGCRSWSPLNDDC-UHFFFAOYSA-N 0.000 description 1
- WXJWUZKCCCKENM-UHFFFAOYSA-N O=C(c([s]c1ccncc11)c1NC(C(F)=C1)=CC=CC1I)NOC1CCNCC1 Chemical compound O=C(c([s]c1ccncc11)c1NC(C(F)=C1)=CC=CC1I)NOC1CCNCC1 WXJWUZKCCCKENM-UHFFFAOYSA-N 0.000 description 1
- BJILHCBOBBRWOQ-UHFFFAOYSA-N OC(C1)CN1C(c([s]c1c2cncc1)c2Nc(ccc(I)c1)c1F)=O Chemical compound OC(C1)CN1C(c([s]c1c2cncc1)c2Nc(ccc(I)c1)c1F)=O BJILHCBOBBRWOQ-UHFFFAOYSA-N 0.000 description 1
- IMRGVWZLCZERSQ-UHFFFAOYSA-N OC(c(cncc1)c1Cl)=O Chemical compound OC(c(cncc1)c1Cl)=O IMRGVWZLCZERSQ-UHFFFAOYSA-N 0.000 description 1
- DVPPCQAPJVHBDX-UHFFFAOYSA-N OCCONC(c([s]c(c1cnc2)c2Cl)c1Nc(ccc(I)c1)c1F)=O Chemical compound OCCONC(c([s]c(c1cnc2)c2Cl)c1Nc(ccc(I)c1)c1F)=O DVPPCQAPJVHBDX-UHFFFAOYSA-N 0.000 description 1
- OMKRALFJWBACBA-UHFFFAOYSA-N OCCONC(c([s]c1c2cncc1)c2Nc(c(F)c1)ccc1I)=O Chemical compound OCCONC(c([s]c1c2cncc1)c2Nc(c(F)c1)ccc1I)=O OMKRALFJWBACBA-UHFFFAOYSA-N 0.000 description 1
- AEVNHDQFAZKULL-UHHCSCCBSA-N OC[C@H](CONC(C(C(c1cnc2)Nc(ccc(I)c3)c3F)Sc1c2Br)=O)O Chemical compound OC[C@H](CONC(C(C(c1cnc2)Nc(ccc(I)c3)c3F)Sc1c2Br)=O)O AEVNHDQFAZKULL-UHHCSCCBSA-N 0.000 description 1
- SOKUSVWTSKGFLS-GFCCVEGCSA-N OC[C@H](CONC(c([s]c1ccncc11)c1Nc(cc1)ccc1I)=O)O Chemical compound OC[C@H](CONC(c([s]c1ccncc11)c1Nc(cc1)ccc1I)=O)O SOKUSVWTSKGFLS-GFCCVEGCSA-N 0.000 description 1
- GDRSLSKQTLGNIS-SNVBAGLBSA-N OC[C@H](CONC(c([s]c1ccncc11)c1Nc(ccc(I)c1)c1Cl)=O)O Chemical compound OC[C@H](CONC(c([s]c1ccncc11)c1Nc(ccc(I)c1)c1Cl)=O)O GDRSLSKQTLGNIS-SNVBAGLBSA-N 0.000 description 1
- UHSLSVVHKMXIAJ-SECBINFHSA-N OC[C@H](CONC(c([s]c1ncncc11)c1Nc(ccc(I)c1)c1F)=O)O Chemical compound OC[C@H](CONC(c([s]c1ncncc11)c1Nc(ccc(I)c1)c1F)=O)O UHSLSVVHKMXIAJ-SECBINFHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83916306P | 2006-08-21 | 2006-08-21 | |
| US60/839,163 | 2006-08-21 | ||
| US87160006P | 2006-12-22 | 2006-12-22 | |
| US60/871,600 | 2006-12-22 | ||
| US91762407P | 2007-05-11 | 2007-05-11 | |
| US60/917,624 | 2007-05-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20090047538A KR20090047538A (ko) | 2009-05-12 |
| KR101475088B1 true KR101475088B1 (ko) | 2014-12-23 |
Family
ID=38800915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097005785A Expired - Fee Related KR101475088B1 (ko) | 2006-08-21 | 2007-08-20 | 아자-벤조티오페닐 화합물 및 사용 방법 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7893085B2 (enExample) |
| EP (1) | EP2069359B1 (enExample) |
| JP (1) | JP5349306B2 (enExample) |
| KR (1) | KR101475088B1 (enExample) |
| AR (1) | AR062469A1 (enExample) |
| AU (1) | AU2007286807B2 (enExample) |
| BR (1) | BRPI0714629A2 (enExample) |
| CA (1) | CA2660963A1 (enExample) |
| CL (1) | CL2007002431A1 (enExample) |
| ES (1) | ES2528797T3 (enExample) |
| IL (1) | IL197060A (enExample) |
| MX (1) | MX2009001875A (enExample) |
| NO (1) | NO20091198L (enExample) |
| PE (2) | PE20081359A1 (enExample) |
| TW (1) | TWI426078B (enExample) |
| WO (1) | WO2008024724A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2069354B1 (en) * | 2006-08-21 | 2011-11-02 | Genentech, Inc. | Aza-benzofuranyl compounds and methods of use |
| US9084781B2 (en) | 2008-12-10 | 2015-07-21 | Novartis Ag | MEK mutations conferring resistance to MEK inhibitors |
| MX340392B (es) | 2010-02-25 | 2016-07-06 | Dana Farber Cancer Inst Inc | Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf. |
| CN103038364A (zh) | 2010-03-09 | 2013-04-10 | 达纳－法伯癌症研究所公司 | 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法 |
| WO2013164769A1 (en) | 2012-05-02 | 2013-11-07 | Lupin Limited | Substituted pyridine compounds as crac modulators |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| CA2890238A1 (en) | 2012-11-02 | 2014-05-08 | Merck Patent Gmbh | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| WO2015196072A2 (en) | 2014-06-19 | 2015-12-23 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| EP3394056B1 (en) | 2015-12-22 | 2021-04-14 | Shy Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| CN109072311A (zh) | 2016-04-15 | 2018-12-21 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
| ES3030506T3 (en) | 2017-05-19 | 2025-06-30 | Nflection Therapeutics Inc | Pyrrolopyridine-aniline compounds for treatment of dermal disorders |
| EP3624795B1 (en) * | 2017-05-19 | 2022-04-20 | NFlection Therapeutics, Inc. | Fused heteroaromatic-aniline compounds for treatment of dermal disorders |
| CA3066939A1 (en) | 2017-06-21 | 2018-12-27 | SHY Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| KR102811888B1 (ko) | 2017-09-08 | 2025-05-27 | 에프. 호프만-라 로슈 아게 | 암의 진단 및 치료 방법 |
| EP3752200A1 (en) | 2018-02-13 | 2020-12-23 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| MX2021000293A (es) | 2018-07-09 | 2021-07-15 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos heterociclicos antihelminticos. |
| CA3120337A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Naphthyridinone-aniline compounds for treatment of dermal disorders |
| JP7546297B2 (ja) | 2018-11-20 | 2024-09-06 | エヌフレクション セラピューティクス インコーポレイテッド | 皮膚障害の処置のためのチエニル－アニリン化合物 |
| MA55141A (fr) | 2018-11-20 | 2021-09-29 | Nflection Therapeutics Inc | Composés cyanoaryl-aniline pour le traitement d'affections de la peau |
| US12391705B2 (en) | 2018-12-19 | 2025-08-19 | Shy Therapeutics, Llc | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| BR112021018631A2 (pt) | 2019-03-19 | 2021-11-23 | Boehringer Ingelheim Animal Health Usa Inc | Compostos anti-helmínticos de aza-benzotiofeno e aza-benzofurano |
| WO2021242581A1 (en) | 2020-05-29 | 2021-12-02 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic heterocyclic compounds |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| UY39995A (es) | 2021-11-01 | 2023-05-15 | Boehringer Ingelheim Vetmedica GmbH | Compuestos de pirrolopiridazina como antihelmínticos |
| WO2024033381A1 (en) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
| WO2026019990A1 (en) | 2024-07-18 | 2026-01-22 | Genentech, Inc. | Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002006213A2 (en) * | 2000-07-19 | 2002-01-24 | Warner-Lambert Company | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| US6469004B1 (en) * | 1999-01-13 | 2002-10-22 | Warner-Lambert Company | Benzoheterocycles and their uses as MEK inhibitors |
| WO2004000846A1 (en) * | 2002-06-20 | 2003-12-31 | Celltech R & D Limited | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors |
| US20050049419A1 (en) * | 2003-09-03 | 2005-03-03 | Eli Wallace | Heterocyclic inhibitors of MEK and methods of use thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5328920A (en) | 1991-04-17 | 1994-07-12 | Hoechst-Roussel Pharmaceuticals Incorporated | Substituted (pyridinylamino)-indoles |
| WO1993001169A2 (en) | 1991-07-05 | 1993-01-21 | Merck Sharp & Dohme Limited | Aromatic compounds, pharmaceutical compositions containing them and their use in therapy |
| US5214204A (en) | 1991-07-19 | 1993-05-25 | Abbott Laboratories | Arylamidoalkyl-n-hydroxyurea compounds having lipoxygenase inhibitory activity |
| DE69216509T2 (de) | 1991-08-12 | 1997-05-28 | Takeda Chemical Industries Ltd | Kondensierte Pyrimidinderivate, ihre Herstellung und ihre Verwendung als Antitumormittel |
| CA2083891A1 (en) | 1991-12-03 | 1993-06-04 | Angus Murray Macleod | Heterocyclic compounds, compositions containing them and their use in therapy |
| JPH05345780A (ja) | 1991-12-24 | 1993-12-27 | Kumiai Chem Ind Co Ltd | ピリミジンまたはトリアジン誘導体及び除草剤 |
| US5852046A (en) | 1993-08-03 | 1998-12-22 | Hoechst Aktiengesellschaft | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them |
| US5350748A (en) | 1993-08-18 | 1994-09-27 | Warner-Lambert Company | 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion |
| DE4425609A1 (de) | 1994-07-20 | 1996-01-25 | Bayer Ag | Benzofuranyl- und Benzothienyloxazolidinone |
| BR9804865B1 (pt) | 1997-04-24 | 2011-08-23 | pesticida 3-(fenil substituìdo)-5-(tienil ou furil)-1,2,4-triazóis, composição para controlar insetos ou ácaros, bem como processo para controlar insetos, ácaros, moscas brancas e afìdios, para proteger plantas de afìdios, ácaros ou insetos. | |
| GB9723590D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| FR2777886B1 (fr) | 1998-04-27 | 2002-05-31 | Adir | Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP0982304B1 (en) | 1998-06-30 | 2002-10-02 | Eli Lilly And Company | Piperidine derivatives having effects on serotonin related systems |
| EP1100501A4 (en) | 1998-06-30 | 2002-12-04 | Lilly Co Eli | PYRROLIDINE AND PYRROLIDINE DERIVATIVES INFLUENTING THE SYSTEMS ASSOCIATED WITH SEROTONIN |
| AU4727799A (en) | 1998-06-30 | 2000-01-17 | Eli Lilly And Company | Azepine derivatives having effects on serotonin related systems |
| US6410562B1 (en) | 1998-12-18 | 2002-06-25 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
| JP2000204079A (ja) * | 1999-01-13 | 2000-07-25 | Warner Lambert Co | ジアリ―ルアミン |
| FR2799756B1 (fr) | 1999-10-15 | 2001-12-14 | Adir | Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AR027133A1 (es) | 1999-12-30 | 2003-03-12 | Lundbeck & Co As H | Derivados de heteroarilo, su preparacion y uso. |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| US6653346B1 (en) | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
| WO2003070731A2 (en) | 2002-02-19 | 2003-08-28 | Pharmacia & Upjohn Company | Azabicyclic compounds for the treatment of disease |
| DE60330227D1 (de) * | 2002-03-13 | 2010-01-07 | Array Biopharma Inc | N3-alkylierte benzimidazol-derivate als mek-hemmer |
| RU2300528C2 (ru) * | 2002-03-13 | 2007-06-10 | Эррэй Биофарма, Инк. | N3-алкилированные бензимидазольные производные в качестве ингибиторов мек |
| US20040009976A1 (en) | 2002-04-30 | 2004-01-15 | Kumiko Takeuchi | Hypoglycemic imidazoline compounds |
| AU2003257145B2 (en) | 2002-08-02 | 2008-11-13 | Merck Sharp & Dohme Corp. | Substituted furo (2,3-b) pyridine derivatives |
| GB0220581D0 (en) | 2002-09-04 | 2002-10-09 | Novartis Ag | Organic Compound |
| CL2003002287A1 (es) * | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| JP2005104838A (ja) | 2003-01-09 | 2005-04-21 | Tanabe Seiyaku Co Ltd | 縮合フラン化合物 |
| GB0316237D0 (en) | 2003-07-11 | 2003-08-13 | Astrazeneca Ab | Therapeutic agents |
| GB0316232D0 (en) | 2003-07-11 | 2003-08-13 | Astrazeneca Ab | Therapeutic agents |
| JP4741491B2 (ja) | 2003-08-07 | 2011-08-03 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 抗増殖剤としての２，４−ピリミジンジアミン化合物および使用 |
| DE10351436A1 (de) | 2003-11-04 | 2005-06-09 | Merck Patent Gmbh | Verwendung von Thienopyrimidinen |
| ES2299906T3 (es) | 2003-11-25 | 2008-06-01 | Eli Lilly And Company | Moduladores de receptores activados por proliferadores de peroxisomas. |
| WO2005058858A1 (en) | 2003-12-19 | 2005-06-30 | Biovitrum Ab | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder |
| WO2005061476A2 (en) | 2003-12-22 | 2005-07-07 | Basilea Pharmaceutica Ag | Aroylfuranes and aroylthiophenes |
| WO2005063296A2 (en) | 2003-12-23 | 2005-07-14 | Pfizer Products Inc. | Therapeutic combination for cognition enhancement and psychotic disorders |
| MX2007012448A (es) * | 2005-04-06 | 2007-10-19 | Astrazeneca Ab | Heterociclos sustituidos y su uso como inhibidores de chk1, pdk1 y pak. |
| AU2006284751A1 (en) | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| EP2069354B1 (en) | 2006-08-21 | 2011-11-02 | Genentech, Inc. | Aza-benzofuranyl compounds and methods of use |
| CA2662285A1 (en) | 2006-08-31 | 2008-03-06 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
-
2007
- 2007-08-20 MX MX2009001875A patent/MX2009001875A/es active IP Right Grant
- 2007-08-20 ES ES07814268.4T patent/ES2528797T3/es active Active
- 2007-08-20 AU AU2007286807A patent/AU2007286807B2/en not_active Ceased
- 2007-08-20 BR BRPI0714629-9A patent/BRPI0714629A2/pt not_active IP Right Cessation
- 2007-08-20 WO PCT/US2007/076340 patent/WO2008024724A1/en not_active Ceased
- 2007-08-20 EP EP07814268.4A patent/EP2069359B1/en active Active
- 2007-08-20 KR KR1020097005785A patent/KR101475088B1/ko not_active Expired - Fee Related
- 2007-08-20 CA CA002660963A patent/CA2660963A1/en not_active Abandoned
- 2007-08-20 JP JP2009525719A patent/JP5349306B2/ja not_active Expired - Fee Related
- 2007-08-20 US US11/894,345 patent/US7893085B2/en not_active Expired - Fee Related
- 2007-08-21 AR ARP070103713A patent/AR062469A1/es unknown
- 2007-08-21 TW TW096130981A patent/TWI426078B/zh not_active IP Right Cessation
- 2007-08-21 PE PE2007001134A patent/PE20081359A1/es not_active Application Discontinuation
- 2007-08-21 CL CL200702431A patent/CL2007002431A1/es unknown
- 2007-08-21 PE PE2011001541A patent/PE20120049A1/es not_active Application Discontinuation
-
2009
- 2009-02-16 IL IL197060A patent/IL197060A/en not_active IP Right Cessation
- 2009-03-20 NO NO20091198A patent/NO20091198L/no not_active Application Discontinuation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6469004B1 (en) * | 1999-01-13 | 2002-10-22 | Warner-Lambert Company | Benzoheterocycles and their uses as MEK inhibitors |
| WO2002006213A2 (en) * | 2000-07-19 | 2002-01-24 | Warner-Lambert Company | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| WO2004000846A1 (en) * | 2002-06-20 | 2003-12-31 | Celltech R & D Limited | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors |
| US20050049419A1 (en) * | 2003-09-03 | 2005-03-03 | Eli Wallace | Heterocyclic inhibitors of MEK and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010501584A (ja) | 2010-01-21 |
| CA2660963A1 (en) | 2008-02-28 |
| NO20091198L (no) | 2009-05-20 |
| EP2069359A1 (en) | 2009-06-17 |
| PE20081359A1 (es) | 2008-11-27 |
| IL197060A0 (en) | 2009-11-18 |
| TWI426078B (zh) | 2014-02-11 |
| IL197060A (en) | 2014-12-31 |
| AR062469A1 (es) | 2008-11-12 |
| JP5349306B2 (ja) | 2013-11-20 |
| EP2069359B1 (en) | 2014-11-12 |
| US20080081821A1 (en) | 2008-04-03 |
| AU2007286807B2 (en) | 2013-03-21 |
| TW200823222A (en) | 2008-06-01 |
| MX2009001875A (es) | 2009-03-02 |
| ES2528797T3 (es) | 2015-02-12 |
| BRPI0714629A2 (pt) | 2013-05-07 |
| PE20120049A1 (es) | 2012-02-16 |
| CL2007002431A1 (es) | 2008-03-14 |
| WO2008024724A1 (en) | 2008-02-28 |
| AU2007286807A1 (en) | 2008-02-28 |
| KR20090047538A (ko) | 2009-05-12 |
| US7893085B2 (en) | 2011-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101475088B1 (ko) | 아자-벤조티오페닐 화합물 및 사용 방법 | |
| RU2441004C1 (ru) | 5-анилиноимидазопиридины и способы их применения | |
| JP5211063B2 (ja) | アザ−インドリル化合物及び使用方法 | |
| JP5710268B2 (ja) | ８−アニリノイミダゾピリジン及びその抗ガン及び／又は抗炎症剤としての使用 | |
| JP5448818B2 (ja) | アザベンゾフラニル化合物および使用方法 | |
| KR20110029161A (ko) | Ｍｅｋ 키나제 억제제로서의 비시클릭 헤테로사이클 | |
| KR20110028376A (ko) | Ｍｅｋ 키나제 억제제로서의 이소인돌론 유도체 및 사용 방법 | |
| KR20100099185A (ko) | 아자인돌리진 및 이용 방법 | |
| CN101583616B (zh) | 氮杂苯并噻吩基化合物及使用方法 | |
| RU2444524C2 (ru) | Азабензотиофенильные соединения и способы применения | |
| RU2448111C2 (ru) | Соединения азабензофуранила и способ их применения | |
| RU2483069C2 (ru) | Азаиндолизины и способы их применения | |
| HK1135099B (en) | Aza-indolyl compounds and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20171216 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20171216 |